Outcomes of Hypofractionated Radiotherapy with Induction or Sequential Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Single Institution Experience

PURPOSE/OBJECTIVE(S)

The standard of care for unresectable stage III non-small cell lung cancer (NSCLC) patients not candidates for concurrent chemotherapy (CT) and radiotherapy (RT) is not well established. Hypofractionated RT (hRT) can be used after CT induction, or, as a bridge to sequential CT to offer a curative intent treatment regimen. Tumor and nodal proximity to mediastinal structures plays an important role regarding the degree of safe hypofractionation. There is limited published evidence related the benefits of hRT combined with induction or sequential CT among this group of patients. We analyzed the outcomes of stage III NSCLC receiving a hRT regimen of 52.5 Gy in 15 fractions alone, or with either induction or sequential CT.

MATERIALS/METHODS

In this retrospective review, patients with stage III NSCLC receiving hRT 52.5 Gy in 15 fractions between 2008 and 2020 were included for analysis. Patients were separated into three cohorts: i) hRT alone, ii) induction CT followed by hRT, and iii) hRT followed by sequential CT. Overall survival (OS) and radiation toxicity (CTCAE v5.0) were analyzed for all 3 cohorts. Patients for whom sequential chemotherapy was planned, but not delivered, were included in cohort ii) through intention-to-treat analysis. The OS at 2 years was statistically evaluated using a log-rank test with alpha set at 0.05.

RESULTS

Eighty-three patients met criteria for analysis with 35, 30, and 18 patients respectively in cohorts i), ii), and iii). Median age at treatment was 75 (43-91) with 53% of patients being men and 43% women. Tumor histology varied between adenocarcinoma (43%), squamous cell carcinoma (44%), and others (13%). The median/2-year OS for cohorts i), ii), and iii) was 8 mo/19%, 25 mo/50%, and 17 mo/72% respectively. OS between any chemotherapy and no chemotherapy was statistically significant (p = 6.1x10-7) while the timing of chemotherapy did not reach statistical significance (p = 0.15). RT was overall well tolerated with grade 1-2 fatigue being the most common side effect (81%), 1 patient had grade 3 pneumonitis, and 1 patient had a rib fracture.

CONCLUSION

Among patients with stage III NSCLCs, moderately hRT of 52.5 Gy in 15 fractions, with either induction or sequential CT appears to provide a survival advantage compared to hRT alone, with an acceptable side-effect profile. The 2-year OS reported here is similar to other published hRT regimens (SOCCAR trial) and conventional fractionation (RTOG0617). Conclusions are limited by the retrospective nature of the study, and the introduction of immunotherapy (IO) for stage III NSCLC in 2019 in Canada. Future work will focus on evaluating dosimetry, the impact of IO, and, patients not included in this analysis that also received this regimen (oligometastasis, locoregional failure, other stages).

Toxicity of Patients with Ultra-Central Thoracic Tumors Treated with Stereotactic Body Radiotherapy (SBRT) with Dose of 50 Gy in 5 Fractions

PURPOSE/OBJECTIVE(S)

The ideal regimen for stereotactic body radiotherapy (SBRT) in ultra-central lung tumors is still to be defined, mostly due to the risk of unacceptable or fatal toxicity. There is not much information on outcomes after SBRT for this group of patients. We summarize here our experience with ultra-central lung cancer patients treated with the dose of 50 Gy delivered in 5 fractions.

MATERIALS/METHODS

This study is a retrospective review of all cases of ultra-central thoracic tumors treated with SBRT with the dose of 50 Gy in 5 fractions, delivered every other day, at our institution. In all cases, as we defined ultra-central lung tumor, the PTV overlapped or touched one or more of the following structures: bronchial tree, trachea, great vessels, heart, and esophagus. Metastatic and primary lung lesions were included. The volumes of treatment were defined by 4D-CT to consider breathing motion. Normal organs constraints followed the recommendations of the RTO 0813 trial as follows: Spinal cord: max 30 Gy. Lung right or lung left: V13 Gy[cc] < 1500. Esophagus: max 52 Gy and nonadjacent esophagus: V27.5 Gy[cc] < 5. Heart: V32 Gy[cc] < 15; max 52 Gy. Great vessels: max 52 Gy and non-adjacent great vessels V47 Gy[cc] < 10. Trachea plus bronchus: max 52 Gy and non-adjacent V18 Gy[cc] < 4. Follow-up, at the discretion of the treating MD, included periodic CT scans of the thorax after SBRT and assessment of radiation-induced toxicity scored with CTCv3.0.

RESULTS

Between December 2015 and February 2022, 86 patients were eligible for this review. Median follow-up was 17 months (range: 1-76 months); the median age was 74 years (range: 37-98 years). Histology was as follows: 50 patients had biopsy proved NSCLC, 16 had no biopsy, and 20 had metastatic non-lung primaries. Overlapped structures were as follows: with great vessels in 46 cases, heart in 20 cases, trachea/branchial tree in 18 cases, and esophagus in 2 cases. In 16 patients the overlap was present in more than one structure. Overall, 68.6% did not report acute toxicity. The most common acute side effects were fatigue (15.1%), coughing (8.1%), shortness of breath (6.9%), esophagitis (2.3%), and dysphagia (1.1%). No grade 3 or more significant toxicity was described. As acute side effects, many patients had exacerbations of the previous condition, such as shortness of breath (16 pts) or coughing (4 pts) during follow-up. Pneumonitis was found as a late side effect in four cases. One patient had empyema associated with a fistula in the non-irradiated lung, where the patient had previous surgery, but in the irradiated lung no severe complication was detected. There were no deaths attributed to the SBRT treatment. 67.5% of 86 patients were alive at the time of the review; 87.2% had local control, and 65.1% had metastases-free survival.

CONCLUSION

In this cohort of patients, no death or even severe acute or chronic toxicity was attributed to SBRT. SBRT seems safe for ultra-central lesions using the regimen of 50 Gy in 5 fractions with the constraints of the RTOG 0813 trial.

Interactions between COVID-19 and Lung Cancer: Lessons Learned during the Pandemic

Simple Summary

COVID-19 is a respiratory infectious disease caused by the coronavirus SARS-CoV-2. Lung cancer is the leading cause of all cancer-related deaths worldwide. As both SARS-CoV-2 and lung cancer affect the lungs, the aim of this narrative review is to provide a consolidation of lessons learned throughout the pandemic regarding lung cancer and COVID-19. Risk factors found in lung cancer patients, such as advanced cancers, smoking, male, etc., have been associated with severe COVID-19. The cancer treatments hormonal therapy, immunotherapy, and targeted therapy have shown no association with severe COVID-19 disease, but chemotherapy and radiation therapy have shown conflicting results. Logistical changes and modifications in treatment plans were instituted during the pandemic to minimize SARS-CoV-2 exposure while maintaining life-saving cancer care. Finally, medications have been developed to treat early COVID-19, which can be highly beneficial in vulnerable cancer patients, with paxlovid being the most efficacious drug currently available.

Abstract

Cancer patients, specifically lung cancer patients, show heightened vulnerability to severe COVID-19 outcomes. The immunological and inflammatory pathophysiological similarities between lung cancer and COVID-19-related ARDS might explain the predisposition of cancer patients to severe COVID-19, while multiple risk factors in lung cancer patients have been associated with worse COVID-19 outcomes, including smoking status, older age, etc. Recent cancer treatments have also been urgently evaluated during the pandemic as potential risk factors for severe COVID-19, with conflicting findings regarding systemic chemotherapy and radiation therapy, while other therapies were not associated with altered outcomes. Given this vulnerability of lung cancer patients for severe COVID-19, the delivery of cancer care was significantly modified during the pandemic to both proceed with cancer care and minimize SARS-CoV-2 infection risk. However, COVID-19-related delays and patients’ aversion to clinical settings have led to increased diagnosis of more advanced tumors, with an expected increase in cancer mortality. Waning immunity and vaccine breakthroughs related to novel variants of concern threaten to further impede the delivery of cancer services. Cancer patients have a high risk of severe COVID-19, despite being fully vaccinated. Numerous treatments for early COVID-19 have been developed to prevent disease progression and are crucial for infected cancer patients to minimize severe COVID-19 outcomes and resume cancer care. In this literature review, we will explore the lessons learned during the COVID-19 pandemic to specifically mitigate COVID-19 treatment decisions and the clinical management of lung cancer patients.

Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities

Glioma are the most common type of malignant brain tumor, with glioblastoma (GBM) representing the most common and most lethal type of glioma. Surgical resection followed by radiotherapy and chemotherapy using the alkylating agent Temozolomide (TMZ) remain the mainstay of treatment for glioma. While this multimodal regimen is sufficient to temporarily eliminate the bulk of the tumor mass, recurrence is inevitable and often poses major challenges for clinical management due to treatment resistance and failure to respond to targeted therapies. Improved tumor profiling capacity has enabled characterization of the genomic landscape of gliomas with the overarching goal to identify clinically relevant subtypes and inform treatment decisions. Increased tumor mutational load has been shown to correlate with higher levels of neoantigens and is indicative of the potential to induce a durable response to immunotherapy. Following treatment with TMZ, a subset of glioma has been identified to recur with increased tumor mutational load. These hypermutant recurrent glioma represent a subtype of recurrence with unique molecular vulnerabilities. In this review, we will elaborate on the current knowledge regarding the evolution of hypermutation in gliomas and the potential therapeutic opportunities that arise with TMZ-induced hypermutation in gliomas.

Elevated ARG1 expression in primary monocytes-derived macrophages as a predictor of radiation-induced acute skin toxicities in early breast cancer patients

Radiation therapy (RT) the front-line treatment after surgery for early breast cancer patients is associated with acute skin toxicities in at least 40% of treated patients. Monocyte-derived macrophages are polarized into functionally distinct (M1 or M2) activated phenotypes at injury sites by specific systemic cytokines known to play a key role in the transition between damage and repair in irradiated tissues. The role of M1 and M2 macrophages in RT-induced acute skin toxicities remains to be defined. We investigated the potential value of M1 and M2 macrophages as predictive factors of RT-induced skin toxicities in early breast cancer patients treated with adjuvant RT after lumpectomy. Blood samples collected from patients enrolled in a prospective clinical study (n = 49) were analyzed at baseline and after the first delivered 2Gy RT dose. We designed an ex vivo culture system to differentiate patient blood monocytes into macrophages and treated them with M1 or M2-inducing cytokines before quantitative analysis of their "M1/M2" activation markers, iNOS, Arg1, and TGFß1. Statistical analysis was performed to correlate experimental data to clinical assessment of acute skin toxicity using Common Toxicity Criteria (CTC) grade for objective evaluation of skin reactions. Increased ARG1 mRNA significantly correlated with higher grades of erythema, moist desquamation, and CTC grade. Multivariate analysis revealed that increased ARG1 expression in macrophages after a single RT dose was an independent prognostic factor of erythema (p = 0 .032), moist desquamation (p = 0 .027), and CTC grade (p = 0 .056). Interestingly, multivariate analysis of ARG1 mRNA expression in macrophages stimulated with IL-4 also revealed independent prognostic value for predicting acute RT-induced toxicity factors, erythema (p = 0 .069), moist desquamation (p = 0 .037), and CTC grade (p = 0 .046). To conclude, our findings underline for the first time the biological significance of increased ARG1 mRNA levels as an early independent predictive biomarker of RT-induced acute skin toxicities.

Triple negative breast cancers comprise a highly tumorigenic cell subpopulation detectable by its high responsiveness to a Sox2 regulatory region 2 (SRR2) reporter

We have recently described a novel phenotypic dichotomy within estrogen receptor-positive breast cancer cells; the cell subset responsive to a Sox2 regulatory region (SRR2) reporter (RR cells) are significantly more tumorigenic than the reporter unresponsive (RU) cells. Here, we report that a similar phenomenon also exists in triple negative breast cancer (TNBC), with RR cells more tumorigenic than RU cells. First, examination of all 3 TNBC cell lines stably infected with the SRR2 reporter revealed the presence of a cell subset exhibiting reporter activity. Second, RU and RR cells purified by flow cytometry showed that RR cells expressed higher levels of CD44, generated more spheres in a limiting dilution mammosphere formation assay, and formed larger and more complex structures in Matrigel. Third, within the CD44^High/CD24⁻ tumor-initiating cell population derived from MDA-MB-231, RR cells were significantly more tumorigenic than RU cells in an in vivo SCID/Beige xenograft mouse model. Examination of 4 TNBC tumors from patients also revealed the presence of a RR cell subset, ranging from 1.1-3.8%. To conclude, we described a novel phenotypic heterogeneity within TNBC, and the SRR2 reporter responsiveness is a useful marker for identifying a highly tumorigenic cell subset within the CD44^High/CD24⁻tumor-initiating cell population.

Profiling gene promoter occupancy of Sox2 in two phenotypically distinct breast cancer cell subsets using chromatin immunoprecipitation and genome-wide promoter microarrays

Introduction

Aberrant expression of the embryonic stem cell marker Sox2 has been reported in breast cancer (BC). We previously identified two phenotypically distinct BC cell subsets separated based on their differential response to a Sox2 transcription activity reporter, namely the reporter-unresponsive (RU) and the more tumorigenic reporter-responsive (RR) cells. We hypothesized that Sox2, as a transcription factor, contributes to their phenotypic differences by mediating differential gene expression in these two cell subsets.

Methods

We used chromatin immunoprecipitation and a human genome-wide promoter microarray (ChIP-chip) to determine the promoter occupancies of Sox2 in the MCF7 RU and RR breast cancer cell populations. We validated our findings with conventional chromatin immunoprecipitation, quantitative reverse transcription polymerase chain reaction (qPCR), and western blotting using cell lines, and also performed qPCR using patient RU and RR samples.

Results

We found a largely mutually exclusive profile of gene promoters bound by Sox2 between RU and RR cells derived from MCF7 (1830 and 456 genes, respectively, with only 62 overlapping genes). Sox2 was bound to stem cell- and cancer-associated genes in RR cells. Using quantitative RT-PCR, we confirmed that 15 such genes, including PROM1 (CD133), BMI1, GPR49 (LGR5), and MUC15, were expressed significantly higher in RR cells. Using siRNA knockdown or enforced expression of Sox2, we found that Sox2 directly contributes to the higher expression of these genes in RR cells. Mucin-15, a novel Sox2 downstream target in BC, contributes to the mammosphere formation of BC cells. Parallel findings were observed in the RU and RR cells derived from patient samples.

Conclusions

In conclusion, our data supports the model that the Sox2 induces differential gene expression in the two distinct cell subsets in BC, and contributes to their phenotypic differences.

Electronic supplementary material

The online version of this article (doi:10.1186/s13058-014-0470-2) contains supplementary material, which is available to authorized users.

Abstract 2493: Identification of MGMT-binding proteins involved in the negative regulation of angiogenesis and invasion

Background: Glioblastoma multiforme (GBM) is the most frequent and most aggressive form of primary malignant brain tumors in adults. The dismal prognosis of GBM patients stems from the highly angiogenic and invasive behavior of GBM tumor cells. O6-methylguanine-DNA methyltransferase (MGMT), a DNA repair protein ubiquitously expressed in normal tissues has been extensively characterized for its role in resistance to alkylating agents used in GBM treatment. We reported for the first time an inverse relationship between expression of MGMT and the angiogenic and invasive profile of GBM cell lines. The mechanisms by which MGMT affects angiogenesis and invasion are unknown. We hypothesized that interactions of MGMT with binding proteins (BPs) may account for additional functions beyond its known role as a DNA repair protein.

Methods: As a first screening to identify MGMT-BPs with a functional relevance for invasion and angiogenesis, we performed affinity purification of MGMT-BPs following overexpression of FLAG-tagged MGMT and mass spectrometry analysis using 293T-Flag/MGMT and control Flag-tagged empty vector (293T-Flag/EV). Lysates were subjected to affinity purification using an anti-Flag monoclonal antibody covalently attached to agarose resin. The affinity bound FLAG fusion proteins were eluted and separated on SDS-PAGE. Coomassie Blue staining enabled the identification of 6 bands including Flag-MGMT in 293T-Flag/MGMT but not the Flag/EV control. The bands were excised from the gel, subjected to trypsin digestion and identified by liquid chromatography-tandem mass spectrometry. The resultant MS/MS spectra were searched against a proteome database for peptide matching and protein identification. Proteins were identified with high confidence using Scaffold software.

Results: Our analysis provided evidence for binding of MGMT to 120 BPs. Using gene ontology (GO) database to search for functional categories, we identified proteins involved in DNA repair, ubiquitin pathway, DNA replication and transcription, RNA metabolism and processing, cell cycle and division, response to stress and cell death. Importantly, we identified proteins involved in cell motility and/or angiogenesis, cytoskeletal-related proteins (15 proteins), small GTPases family and their regulators (10 proteins, such as Rho guanine nucleotide exchange factor 2) and two proteins involved in angiogenesis (Endoribonuclease Dicer and Ribonuclease inhibitor). We also used T98G a human GBM cell line with constitutive expression of MGMT to perform immunoprecipitation of endogenous MGMT (anti-MGMT antibody or the IgG1 isotype control). Mass spectrometry and proteomic analysis of MGMT-BPs in T98G is underway.

Conclusion: Our data provide new structural aspects of MGMT and shed light into the multifaceted role of MGMT, which may lead to the identification of novel therapeutic targets in GBM.

Citation Format: Siham Sabri, Yaoxian Xu, Nicolas Stifani, Bassam S. Abdulkarim. Identification of MGMT-binding proteins involved in the negative regulation of angiogenesis and invasion. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2493. doi:10.1158/1538-7445.AM2013-2493

Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy

PURPOSE

To evaluate the risk of locoregional recurrence (LRR) associated with locoregional treatment of women with primary breast cancer tumors negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (triple-negative breast cancer [TNBC]).

PATIENTS AND METHODS

Patients diagnosed with TNBC were identified from a cancer registry in a single institution (n=768). LRR-free survival was estimated using Kaplan-Meier analysis. The Cox proportional hazards regression model was used to determine risk of LRR on the basis of locoregional management: breast-conserving therapy (BCT; ie, lumpectomy and adjuvant radiation therapy [RT]) and modified radical mastectomy (MRM) in the TNBC population and T1-2N0 subgroup.

RESULTS

At a median follow-up of 7.2 years, 77 patients (10%) with TNBC developed LRR. Five-year LRR-free survival was 94%, 85%, and 87% in the BCT, MRM, and MRM + RT groups, respectively (P < .001). In multivariate analysis, MRM (compared with BCT), lymphovascular invasion and lymph node positivity were associated with increased LRR. Conversely, adjuvant chemotherapy was associated with decreased risk of LRR. For patients with T1-2N0 tumors, 5-year LRR-free survival was 96% and 90% in the BCT and MRM groups, respectively (P = .027), and MRM was the only independent prognostic factor associated with increased LRR compared with BCT (hazard ratio, 2.53; 95% CI, 1.12 to 5.75; P = .0264).

CONCLUSION

Women with T1-2N0 TNBC treated with MRM without RT have a significant increased risk of LRR compared with those treated with BCT. Prospective studies are warranted to investigate the benefit of adjuvant RT after MRM in TNBC.

Abstract 3740: Circulating endothelial progenitor cells as a predictive biomarker of acute skin toxicity in early breast cancer patients undergoing radiation therapy

Background/Purpose: Acute skin toxicity is a common side effect of radiation therapy (RT) in breast-cancer patients. We hypothesized that RT modulates the levels of circulating endothelial cells with a progenitor-like phenotype (EPCs) and/or circulating endothelial cells (CECs), which in turn may affect the repair of radiation injury. So far, the association between the mobilization of EPCs, the levels of CECs and RT-induced skin toxicity has not been investigated in breast cancer patients. We assessed whether RT increased the levels of EPCs and/or CECs and whether this increase may predict RT-induced skin toxicity in early breast cancer patients undergoing RT in a prospective clinical study.

Patients/Methods: Sixty-five early breast cancer patients were treated with adjuvant RT after lumpectomy. The dose delivered to the entire breast was 50 Gy in 25 fractions over 5 weeks. Patients were evaluated weekly for acute skin toxicity using the National Cancer Institute's Common Toxicity Criteria, version 3.0. EPCs (CD45dim, CD31+ and CD133+), CECs (CD45-, CD31+ and CD146+), and vascular endothelial growth factor receptor 2 (VEGFR-2)-positive cells (CD45dim, CD31+ and VEGFR-2+) were enumerated from blood samples by multicolor flow cytometry before RT (T1) and 24h post-RT (T3). Total RNA was extracted from blood samples and the levels of CD133, CD146 and VEGFR-2 were determined using quantitative real-time reverse transcription polymerase chain reaction (Q-RT-PCR).

Results: Flow cytometry analysis revealed that RT within 24h significantly increased EPCs (CD45dim, CD31+ and CD133+, p = 0.0027), (CD45dim, CD31+, VEGFR-2+, p = 0.0020)-positive cells, but not CECs (CD45-, CD31+ and CD146+, p = 0.8415) using Chi-square test. Increased EPCs was highly correlated to the increase of (CD45dim, CD31+, VEGFR-2+)-positive cells using Pearson correlation coefficient (p = 0.0118). Accordingly, as assessed by Q-RT-PCR, expression of CD133 and VEGFR-2, but not CD146 was significantly increased (p = 0.0027; p = 0.1615; p = 0.5485, using normalized gene expression values). Univariate analysis showed that increased CD133 or VEGFR-2 levels, 24h following RT was significantly correlated with acute toxicity (logrank p-value 0.0163; 0.0025, respectively).

Conclusions: Our preliminary results suggest that focal RT is able to induce a systemic response, which promotes rapid mobilization of bone marrow-derived cells EPCs (within 24h), and does not significantly affect the levels of CECs. Furthermore, quantitative analysis of EPCs levels by flow cytometry or Q-RT-PCR correlates with increased acute skin toxicity. Our findings suggest for the first time that mobilization of EPCs following RT could be proposed as an early surrogate biomarker for acute skin toxicity in breast cancer patients.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3740.

Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer

PURPOSE Brain metastasis is usually a fatal event in patients with stage IV breast cancer. We hypothesized that its occurrence can be predicted if a clinical nomogram can be developed, thus allowing for selection of enriched patient populations for prevention trials. PATIENTS AND METHODS Electronic medical records of patients with metastatic breast cancer were retrospectively reviewed for the period between January 2000 and February 2007 under a study approved by the institutional review board. A multivariate logistic regression analysis of selected prognostic features was done. A nomogram to predict brain metastasis was constructed and validated in a cohort of 128 patients with brain metastasis treated at the Cross Cancer Institute (Edmonton, Alberta, Canada). Results Of 2,136 patients with breast cancer, 362 developed subsequent brain metastasis. Age, grade, negative status of estrogen receptor and human epidermal growth factor receptor 2, number of metastatic sites (one v > one), and short disease-free survival were significantly and independently associated with subsequent brain metastasis. The nomogram showed an area under the receiver operating characteristic curve (AUC) of 0.68 (95% CI, 0.66 to 0.69) in the training set. The validation set showed a good discrimination with an AUC of 0.74 (95% CI, 0.70 to 0.79). The nomogram was well calibrated, with no significant difference between the predicted and the observed probabilities. CONCLUSION We have developed a robust tool that is able to predict subsequent brain metastasis in patients with breast cancer with nonbrain metastatic disease. Selection of an enriched patient population at high risk for brain metastasis will facilitate the design of trials aiming at its prevention.

Skin-sparing radiation using intensity-modulated radiotherapy after conservative surgery in early-stage breast cancer: a planning study

PURPOSE

To evaluate the feasibility of skin-sparing by configuring it as an organ-at-risk (OAR) while delivering whole-breast intensity-modulated radiotherapy (IMRT) in early breast cancer.

METHODS AND MATERIALS

Archival computed tomography scan images of 14 left-sided early-breast tumor patients who had undergone lumpectomy were selected for this study. Skin was contoured as a 4- to 5-mm strip extending from the patient outline to anterior margin of the breast planning target volume (PTV). Two IMRT plans were generated by the helical tomotherapy approach to deliver 50 Gy in 25 fractions to the breast alone: one with skin dose constraints (skin-sparing plan) and the other without (non-skin-sparing plan). Comparison of the plans was done using a two-sided paired Student t test.

RESULTS

The mean skin dose and volume of skin receiving 50 Gy were significantly less with the skin-sparing plan compared with non-skin-sparing plan (42.3 Gy vs. 47.7 Gy and 12.2% vs. 57.8% respectively; p < 0.001). The reduction in skin dose was confirmed by TLD measurements in anthropomorphic phantom using the same plans. Dose-volume analyses for other OARs were similar in both plans.

CONCLUSIONS

By configuring the skin as an OAR, it is possible to achieve skin dose reduction while delivering whole-breast IMRT without compromising dose profiles to PTV and OARs.